AR002732A1 - Derivados de 1,3-dihidro-1-(fenilalquilo)-2-h-imidazol-2-ona, uso de los derivados para preparar un medicamento, composiciones farmacéuticas que contienen dichos derivados, un procedimiento para su preparación, y un procedimiento para preparar dichos derivados - Google Patents
Derivados de 1,3-dihidro-1-(fenilalquilo)-2-h-imidazol-2-ona, uso de los derivados para preparar un medicamento, composiciones farmacéuticas que contienen dichos derivados, un procedimiento para su preparación, y un procedimiento para preparar dichos derivadosInfo
- Publication number
- AR002732A1 AR002732A1 ARP960102076A AR10207696A AR002732A1 AR 002732 A1 AR002732 A1 AR 002732A1 AR P960102076 A ARP960102076 A AR P960102076A AR 10207696 A AR10207696 A AR 10207696A AR 002732 A1 AR002732 A1 AR 002732A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- alkyl
- formula
- prepare
- procedure
- Prior art date
Links
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 208000012657 Atopic disease Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- -1 bicyclo [2.2.1] -2-heptenyl Chemical group 0.000 abstract 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención describe el uso de derivados de 1,3-dihidro-1- (fenilalquilo)-2H-imidazol-2-ona para la fabricación de un medicamento para eltratamiento de animales de sangre caliente que padecen de estados de enfermedad relacionados conuna actividad enzimática o catalítica anormal de lafosfodiesterasa IV (PDE IV), y/o estados de enfermedad relacionados con un exceso fisiológicamente perjudicial de citoquinas, en particular enfermedadesalérgicas, atópicas e inflamatorias, donde dichos derivados presentan la fórmula (I), las formas de N-óxido, las sales de adición de ácido o de basefarmacéuticamente aceptables y las formas estereoquímicamente isoméricas de los mismos; donde R1 y R2 independientemente entre sí representan hidrógeno;alquilo C1-6, difluormetilo; trifluormetilo; cicloalquilo C3-6; un heterociclo de 5-6- ó 7-miembros saturado conteniendo 1 ó 2 heteroátomos seleccionadosentre oxígeno, azufre ó nitrógeno; indanilo; biciclo[2.2.1]-2-heptenilo;biciclo[2.2.1]heptanilo; alquilsulfonilo C1-6; arilsulfonilo; o alquilo C1-10substituido; R3 representa H, halo o alquiloxi C1-6; R4 representa H, halo, alquilo C1-6 eventualmente substituido; trifluormetilo; cicloalquilo C3-6;carboxilo; alquiloxicarbonilo C1-4; ciclo-alquilaminocarbonilo C3-6; arilo; Het 1; ó R4 es un radical de la fórmula: -O-R6; ó -NH-R7; R5 es hidrógeno, halo,hidroxi o alquilo C1-6; ó R4 y R5 conjuntamente pueden formar un radical bivalente de la fórmula:-(CH2)n-;-CH2-CH2-O-CH2-CH2-; -CH2-CH2-N(R8)-CH2-CH2-;ó -CH2-CH=CH-CH2-;Y es un enlace directo,haloalcandiilo C1-4 ó alcandiilo C1-4; -A-B- es un radical bivalente de la fórmula:-CR9=CR10; ó -CHR9CHR10-; ó -CHR9-CHR10-; y L representa H; alquilo C1-6 eventualmente sustituido;alquilcarbonilo C1-6 alquiloxicarbonilo C1-6; alquenilo C3-6 eventualmente substituido;
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95200868 | 1995-04-06 | ||
| EP95202898 | 1995-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR002732A1 true AR002732A1 (es) | 1998-04-29 |
Family
ID=26139205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960102076A AR002732A1 (es) | 1995-04-06 | 1996-04-03 | Derivados de 1,3-dihidro-1-(fenilalquilo)-2-h-imidazol-2-ona, uso de los derivados para preparar un medicamento, composiciones farmacéuticas que contienen dichos derivados, un procedimiento para su preparación, y un procedimiento para preparar dichos derivados |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US5994376A (es) |
| EP (1) | EP0819122B1 (es) |
| JP (1) | JP4562101B2 (es) |
| KR (1) | KR100406628B1 (es) |
| CN (1) | CN1068591C (es) |
| AR (1) | AR002732A1 (es) |
| AT (1) | ATE214052T1 (es) |
| AU (1) | AU702947B2 (es) |
| CA (1) | CA2216653C (es) |
| CY (1) | CY2328B1 (es) |
| CZ (1) | CZ293127B6 (es) |
| DE (1) | DE69619661T2 (es) |
| DK (1) | DK0819122T3 (es) |
| ES (1) | ES2174064T3 (es) |
| HR (1) | HRP960155A2 (es) |
| HU (1) | HU223324B1 (es) |
| IL (1) | IL117807A (es) |
| MX (1) | MX9707652A (es) |
| MY (1) | MY119254A (es) |
| NO (1) | NO314339B1 (es) |
| NZ (1) | NZ304877A (es) |
| PL (1) | PL187375B1 (es) |
| PT (1) | PT819122E (es) |
| SI (1) | SI0819122T1 (es) |
| TW (1) | TW332201B (es) |
| WO (1) | WO1996031485A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703098A (en) * | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
| TW332201B (en) | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
| TR199900732T2 (xx) * | 1996-10-02 | 1999-08-23 | Janssen Pharmaceutica N.V. | PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri. |
| JP2002508001A (ja) | 1997-07-10 | 2002-03-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｉｌ−５インヒビターとしての６−アザウラシル誘導体 |
| US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| IL138745A0 (en) * | 1998-04-01 | 2001-10-31 | Janssen Pharmaceutica Nv | Pde iv inhibiting pyridine derivatives |
| US6118017A (en) * | 1998-04-14 | 2000-09-12 | Smithkline Beecham Corporation | Substituted-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenylcyanocyclobutan-1-one |
| CA2328250A1 (en) * | 1998-04-14 | 1999-10-21 | Cornelia Jutta Forster | Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds |
| ES2198980T3 (es) * | 1998-11-23 | 2004-02-01 | Janssen Pharmaceutica N.V. | Derivados de 6-azauralico inhibidores de il-5. |
| DE69936396T2 (de) | 1998-12-18 | 2008-06-19 | Janssen Pharmaceutica N.V. | Il-5 hemmende 6-uracilderivate |
| WO2002022123A1 (en) * | 2000-09-13 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| MXPA03010679A (es) * | 2001-05-23 | 2004-03-02 | Tanabe Seiyaku Co | Una composicion para acelerar la cicatrizacion de fractura osea. |
| CN1537018A (zh) | 2001-05-23 | 2004-10-13 | 田边制药株式会社 | 一种用于软骨疾病再生治疗的组合物 |
| US6706739B2 (en) * | 2001-08-21 | 2004-03-16 | National Health Research Institute | Imidazolidinone compounds |
| SE0200667D0 (sv) * | 2002-03-05 | 2002-03-05 | A & Science Invest Ab | Novel use of cytokine inhibitors |
| GB0326407D0 (en) * | 2003-11-12 | 2003-12-17 | Glaxo Group Ltd | Chemical compounds |
| GB0412865D0 (en) * | 2004-06-09 | 2004-07-14 | Glaxo Group Ltd | Chemical compounds |
| AU2005260328B2 (en) * | 2004-07-05 | 2009-10-01 | Dong Wha Pharmaceutical Co., Ltd. | Composition for the prevention and treatment of allergic inflammatory disease |
| AR057455A1 (es) * | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| WO2007085357A1 (en) * | 2006-01-30 | 2007-08-02 | Euro-Celtique S.A. | Cyclourea compounds as calcium channel blockers |
| US7674811B2 (en) | 2006-03-14 | 2010-03-09 | Ranbaxy Laboratories Limited | 5-lipoxygenase inhibitors |
| US7390772B2 (en) * | 2006-05-18 | 2008-06-24 | International Flavor & Fragrances Inc. | 1-phenyl-spiro[2.5]octane-1-carbonitrile analogues their use in fragrance formulations |
| EP2155226A4 (en) * | 2007-06-14 | 2010-07-28 | Univ California | COMPOUNDS FOR INHIBITING THE PROTEIN AGGREGATION AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| KR101512548B1 (ko) * | 2010-03-12 | 2015-04-15 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| NZ630803A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Optically active pde10 inhibitor |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| AU2016250843A1 (en) | 2015-04-24 | 2017-10-12 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL285394A (es) * | 1961-11-17 | |||
| US3184060A (en) | 1963-02-13 | 1965-05-18 | Owens Illinois Glass Co | Packaging tacky latex emulsion paints in containers manufactured from polyolefinic maerials |
| AU9030691A (en) * | 1990-11-06 | 1992-05-26 | Smithkline Beecham Corporation | Imidazolidinone compounds |
| CA2400368A1 (en) * | 1992-12-02 | 1994-06-09 | Allen J. Duplantier | Catechol diethers as selective pde iv inhibitors |
| TW263495B (es) * | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9304920D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| TW332201B (en) | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
-
1996
- 1996-03-22 TW TW085103447A patent/TW332201B/zh not_active IP Right Cessation
- 1996-03-28 AU AU52755/96A patent/AU702947B2/en not_active Expired
- 1996-03-28 ES ES96909150T patent/ES2174064T3/es not_active Expired - Lifetime
- 1996-03-28 PT PT96909150T patent/PT819122E/pt unknown
- 1996-03-28 MX MX9707652A patent/MX9707652A/es unknown
- 1996-03-28 HU HU9801575A patent/HU223324B1/hu active IP Right Grant
- 1996-03-28 US US08/930,296 patent/US5994376A/en not_active Expired - Lifetime
- 1996-03-28 DK DK96909150T patent/DK0819122T3/da active
- 1996-03-28 CZ CZ19973149A patent/CZ293127B6/cs not_active IP Right Cessation
- 1996-03-28 CA CA002216653A patent/CA2216653C/en not_active Expired - Lifetime
- 1996-03-28 WO PCT/EP1996/001394 patent/WO1996031485A1/en not_active Ceased
- 1996-03-28 AT AT96909150T patent/ATE214052T1/de active
- 1996-03-28 DE DE69619661T patent/DE69619661T2/de not_active Expired - Lifetime
- 1996-03-28 EP EP96909150A patent/EP0819122B1/en not_active Expired - Lifetime
- 1996-03-28 JP JP52995996A patent/JP4562101B2/ja not_active Expired - Lifetime
- 1996-03-28 PL PL96322654A patent/PL187375B1/pl unknown
- 1996-03-28 CN CN96193101A patent/CN1068591C/zh not_active Expired - Lifetime
- 1996-03-28 SI SI9630434T patent/SI0819122T1/xx unknown
- 1996-03-28 KR KR1019970706853A patent/KR100406628B1/ko not_active Expired - Lifetime
- 1996-03-28 NZ NZ304877A patent/NZ304877A/en not_active IP Right Cessation
- 1996-04-02 HR HR95202898.3A patent/HRP960155A2/hr not_active Application Discontinuation
- 1996-04-03 AR ARP960102076A patent/AR002732A1/es active IP Right Grant
- 1996-04-03 IL IL11780796A patent/IL117807A/en not_active IP Right Cessation
- 1996-04-05 MY MYPI96001300A patent/MY119254A/en unknown
-
1997
- 1997-10-06 NO NO19974602A patent/NO314339B1/no not_active IP Right Cessation
-
1999
- 1999-07-27 US US09/362,007 patent/US6403805B1/en not_active Expired - Lifetime
-
2002
- 2002-07-15 CY CY0200043A patent/CY2328B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR002732A1 (es) | Derivados de 1,3-dihidro-1-(fenilalquilo)-2-h-imidazol-2-ona, uso de los derivados para preparar un medicamento, composiciones farmacéuticas que contienen dichos derivados, un procedimiento para su preparación, y un procedimiento para preparar dichos derivados | |
| ES2871027T3 (es) | Inhibidores potentes de la epóxido hidrolasa soluble | |
| ATE197672T1 (de) | Arzneimittel gegen nervöse erkrankungen | |
| NO169286C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolin-2-okso-1-karboksylsyrederivater | |
| ATE150749T1 (de) | Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel | |
| AR039567A1 (es) | Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa, composicion farmaceutica y procedimiento de preparacion del compuesto | |
| AR012593A1 (es) | Pirrolopiridinas sustituidas, composicion farmaceutica que las contiene, procedimiento para su preparacion y el uso de las mismas en la manufacturade un medicamento | |
| SE0203654D0 (sv) | New compounds | |
| NO172580C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte n-(1-alkyl-3-hydroksy-4-piperidinyl)benzamider | |
| ATE448194T1 (de) | Verwendung einer pharmazeutischen zusammensetzung mit einem para-aminophenylessigsäurederivat für die behandlung von entzündlichen erkrankungen des magen-darmtrakts | |
| LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| AR008875A1 (es) | Derivados de 2-cianoiminoimidazol inhibidores de pde iv, procedimiento para su preparacion, composicion que los contienen, procedimiento para preparar dicha composicion y uso de dichos compuestos para la preparacion de medicamentos. | |
| AR016422A1 (es) | Compuestos de esteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p; composiciones farmaceuticas y procedimientos detratamiento. | |
| NO933201L (no) | Substituerte cykloheksanderivater for behandling av sykdommer | |
| US20090123389A1 (en) | Methods for modulating Th17 cell development in the treatment and prevention of cellulite | |
| ATE440838T1 (de) | Pharmazeutisch aktive sulfonylaminosäurederivate | |
| AR003412A1 (es) | Derivados de 1,3-dihidro-1-(fenilalquenil)-2h-imidazol-2-ona, procedimiento para su preparacion, composicion que los comprenden, procedimiento para obtenerdicha composicion y uso de dichos compuestos para preparar medicamentos. | |
| ATE157871T1 (de) | Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind | |
| ATE507226T1 (de) | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung | |
| DE69525633D1 (de) | Chinoxalinderivate und ihre therapeutische verwendbarkeit | |
| ES2133358T3 (es) | Compuestos de carbapenem como antibioticos. | |
| EA200001009A1 (ru) | Производные пиридина, ингибирующие фосфодиэстеразу iv | |
| AR007369A1 (es) | El uso de derivados carboxilados y un medicamento que contiene uno o mas de dichos derivados | |
| EP1075261A1 (en) | Mycobacterial inhibitors | |
| NO160300C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive penicillinderivater. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |